Abstract:Traditionally, drugs are monovalent, targeting only one site on the protein surface. This includes orthosteric and allosteric drugs, which bind the protein at orthosteric and allosteric sites, respectively. Orthosteric drugs are good in potency, whereas allosteric drugs have better selectivity and are solutions to classically undruggable targets. However, it would be difficult to simultaneously reach high potency and selectivity when targeting only one site. Also, both kinds of monovalent drugs suffer from mutation-caused drug resistance. To overcome these obstacles, dualsteric modulators have been proposed in the past twenty years. Compared to orthosteric or allosteric drugs, dualsteric modulators are bivalent (or bitopic) with two pharmacophores. Each of the two pharmacophores bind the protein at the orthosteric and an allosteric site, which could bring the modulator with special properties beyond monovalent drugs. In this study, we comprehensively review the current development of dualsteric modulators. Our main effort reason and illustrate the aims to apply the dualsteric approach, including a "double win" of potency and selectivity, overcoming mutation-caused drug resistance, developments of function-biased modulators, and design of partial agonists. Moreover, the strengths of the dualsteric technique also led to its application outside pharmacy, including the design of highly sensitive fluorescent tracers and usage as molecular rulers. Besides, we also introduced drug targets, designing strategies, and validation methods of dualsteric modulators. Finally, we detail the conclusions and perspectives. Dualsteric modulators are praised for a balance of potency and selectivity, overcoming drug resistance, function bias, and an easy scheme for partial agonist. It could also be used to design fluorescent tracers and study protein conformations.

Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators

Drug design targeting active posttranslational modification protein isoforms

Designed dualsteric modulators: A novel route for drug discovery

A quantitative view of strategies to engineer cell-selective ligand binding

Designing drugs and chemical probes with the dualsteric approach

Insights into the selective mechanism of PDE2/9a inhibitors from silico aspects

Protein isoform-centric therapeutics: expanding targets and increasing specificity

A Structure-based Allosteric Modulator Design Paradigm

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

In-Silico Approaches to Multi-target Drug Discovery

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

Allosteric Modulator Discovery: from Serendipity to Structure-Based Design.

Computational Methods-Guided Design of Modulators Targeting Protein-Protein Interactions (Ppis)

Structure-Guided Inhibitor Design Expands the Scope of Analog-Sensitive Kinase Technology

Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity

Multiple target-based pharmacophore design from active site structures

Molecular Design Strategy of Protein Isoform-Specific Fluorescent Probes by Considering Molecule in Its Entirety

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design

Recent advances and method development for drug target identification

Toward understanding the molecular basis for chemical allosteric modulator design